2017年版《国家医保药品目录》解读

Decipherment and Consideration of 2017th Edition of National Health Insurance Directory

目的比较2017年版《国家医保药品目录》和2009年版《国家医保药品目录》的差异,探讨《国家医保药品目录》调整特点,为新一轮省级医保目录调整提供参考。方法分别从治疗分类、药品名称、剂型和支付范围4个方面,采用Excel 2016对两版《国家医保药品目录》纳入的药品进行比对分析。结果 2017年版《国家医保药品目录》调整包括调进调出、修改支付范围、调整药品分类和编码等。新增339个品种,其中西药133个品种,增幅约11.4%,中成药206个品种,增幅约20.0%,此外,149个品种新增剂型。新增品种及剂型主要集中在治疗高血压及糖尿病等慢病、肿瘤等重大疾病的药物,创新药以及儿童用药。结论 2017年版《国家医保药品目录》调整,体现了"补缺、选优、支持创新、鼓励竞争"的政策思路。同时,其治疗分类、药物名称及编码更加科学合理。

ObjectiveTo provide reference for the adjustment of provincial health insurance directory by comparing the differences between2017and2009edition of National Health Insurance Directory(NHID)and exploring the characteristics of NHID adjustment.MethodsThe Excel2016was used to carry out a comparative analysis of the drugs included in the two editions of NHID from the4aspects such as classification,drug name,dosage form and payment range.ResultsThe adjustments of NHID in2017include drug variety,payment range,drug classification and coding.A total of339drugs were added,of which133were chemical drugs with a growth rate of11.4%,and206were Traditional Chinese Medicine with a growth rate of20.0%.In addition,dosage form was added in149drug varieties.The adjustment mainly focuses on chronic diseases such as hypertension and diabetes,serious diseases such as cancer,innovative drugs,and pediatric drugs.ConclusionThe adjustment of2017edition of NHID embodied the policy thinking of"filling,selecting,supporting innovation and encouraging competition".Moreover,the drug classification,name and coding are more scientific and reasonable.